FDA approves Zemdri for UTIs but not bloodstream infections

The US FDA has approved Zemdri (plazomicin) for use in adults with complicated urinary tract infections (cUTIs) caused by certain Enterobacteriaceae. However, it isn’t all good news as the agency has also issued a response for bloodstream infections, noting there isn’t substantial evidence of Zemdri’s effectiveness.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.

Antibiotics Drug Development Industry